Neumora Therapeutics, Inc. Stock: price and insider trades · United States

Neumora Therapeutics, Inc. is a listed company based in United States. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 38 filings signed by 6 insiders.

Both sides are active: 1 purchase worth €4.3M and 16 sales worth €939k, from 1 insider and 4 insiders respectively. The net balance comes to €3.4M on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Burow Kristina filed the largest purchase, €4.3M, on 29 October 2025. The buyers include 1 senior executive.

For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 38 filings here. Since 2023, the database holds 11 purchases and 26 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -236.9 m USD.

In the case of 1 purchase, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 29 October 2025, 354 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.